Cigna Group (CI): Assessing Valuation as Analyst Optimism Rises Ahead of Q3 2025 Earnings

The Cigna Group (CI) is drawing fresh attention from investors ahead of its upcoming Q3 2025 earnings report. Recent analyst coverage has been upbeat, citing strong results and a solid track record with dividends.

See our latest analysis for Cigna Group.

Cigna Group’s share price has steadily advanced this year, up 9.0% year-to-date, as the company’s solid revenue growth and recent analyst optimism continue to catch investors’ attention. While the 1-year total shareholder return is still in the red, longer-term holders have seen gains, with a notable total return of 76.3% over the past five years. This suggests that momentum could be picking back up as sentiment swings positive ahead of earnings and following a series of upbeat industry ratings.

If you’re interested in other healthcare names gaining traction, be sure to check out the latest movers in our curated list: See the full list for free.

With shares trading at a considerable discount to most analyst price targets and earnings expectations running high, the question now is whether Cigna Group is truly undervalued or if the market has already priced in the next stage of growth.

Most Popular Narrative: 18.9% Undervalued

Cigna Group’s last close was $299.27, while the most popular narrative projects a fair value nearly 19% higher. This narrative focuses on specialty pharmacy’s growth, digital innovation, and demographic tailwinds as key drivers for continued market outperformance.

Cigna is capitalizing on the growing demand for specialty pharmacy and care services. Particularly as chronic diseases and complex treatments become more prevalent, the double-digit revenue growth in CuraScript and Accredo positions the company to capture an expanding portion of the high-growth $400B+ specialty space, supporting long-term revenue and earnings growth. The increasing aging population and rising chronic disease rates globally continue to propel higher healthcare utilization. This drives up demand for integrated solutions across Cigna's Evernorth and Cigna Healthcare platforms. This demographic tailwind is expected to expand Cigna's member base and premium revenues.

Read the complete narrative.

Want to know why analysts are betting on Cigna's future? The secret is a combination of rising margins, bold earnings forecasts, and a significant jump in revenue ahead. Get the full story on what’s fueling this optimistic price target and see which numbers might surprise you behind the scenes.

Result: Fair Value of $369.13 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, significant regulatory shifts or pressure to reduce costs in pharmacy services could present challenges for Cigna Group's margin outlook and long-term growth story.

Find out about the key risks to this Cigna Group narrative.

Build Your Own Cigna Group Narrative

If you want to draw your own conclusions or dig into the numbers differently, you can craft a fresh perspective in just minutes. Do it your way

A great starting point for your Cigna Group research is our analysis highlighting 6 key rewards and 1 important warning sign that could impact your investment decision.

Looking for more smart investment ideas?

Unlock your investing potential by tapping into powerful trends and unique opportunities others may overlook. Let Simply Wall Street help you find your next advantage:

• Tap into tomorrow’s tech with these 24 AI penny stocks, where groundbreaking artificial intelligence companies are shaping the competitive edge of every industry.
• Grab the chance for steady income by reviewing these 18 dividend stocks with yields > 3%, a list of stocks featuring attractive yields above 3% for resilient portfolios.
• Position yourself ahead of the curve with these 26 quantum computing stocks, giving you exposure to pioneering breakthroughs in quantum computing and disruptive digital innovation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com